Healthcare Industry News: Hyperion Therapeutics
News Release - September 5, 2007
NEA Participates in $40M Investment in Hyperion TherapeuticsDemonstrates Continued Commitment to Outstanding Teams and Products
MENLO PARK, Calif.--(HSMN NewsFeed)--New Enterprise Associates (NEA) has invested in South San Francisco, CA-based Hyperion Therapeutics, a biopharmaceutical company focused on the development and commercialization of gastrointestinal and hepatology therapies for the treatment of Urea Cycle Disorders (UCD) and Hepatic Encephalopathy (HE). NEA joins Sofinnova Ventures, Highland Capital Partners, and WRF Capital in this $40 million Series B financing.
Proceeds from this $40 million financing will be used to complete the company's licensing agreement with Medicis Pharmaceutical Corporation, build out the management team, advance clinical trials and begin US promotion of the only two FDA approved compounds for the treatment of UCD, AMMONULŪ (sodium phenylacetate and sodium benzoate) Injection 10%/10% and BUPHENYLŪ (sodium phenylbutyrate). An urea cycle disorder is an inherited, inborn error of the metabolism. Patients with UCD lack or are deficient in one of the key enzymes that comprise the urea cycle, the body's primary vehicle for removing ammonia from the bloodstream, which, left untreated, can result in brain damage, coma or death.
"NEA and this group of investors will make it possible for Hyperion to have immediate and significant impact on patient lives," said Chris Rivera, President and CEO of Hyperion. "We searched for investment partners that saw the critical need for the solution to the problems we solved, and are thrilled with this investment consortium. We welcome NEA, Mike and their experience and guidance to the Board. This along with our other investors and Board members will aide Hyperion in achieving its corporate objectives."
About Hyperion Therapeutics
Hyperion Therapeutics is a specialty therapeutics company focused on becoming a global leader in gastrointestinal (GI) and hepatology therapeutic programs and products that address underserved patient populations or unmet medical needs to improve patient care. The company has assembled a seasoned executive team with extensive industry experience developing and commercializing specialty pharmaceutical products. Hyperion is headquartered in South San Francisco, CA. For additional information, visit: www.hyperiontx.com.
New Enterprise Associates (NEA) is a leading venture capital firm focused on helping entrepreneurs create and build major new enterprises that use technology to improve the way we live, work and play. Since its founding in 1978, the firm has followed the same core principles: supporting its entrepreneurs, providing an excellent return to its limited partners and practicing its profession with the highest standards and respect. NEA focuses on investments at all stages of a company's development, from seed-stage through IPO. With approximately $8.5 billion in committed capital, NEA's experienced management team has invested in over 550 companies, of which more than 160 have gone public and more than 230 have been acquired. NEA has US offices in Chevy Chase, Maryland, Menlo Park, California and Baltimore, Maryland. In addition, New Enterprise Associates (India) Pvt. Ltd. has an office in Bangalore, India and New Enterprise Associates (Beijing) Ltd. has offices in Beijing and Shanghai, China. For additional information, visit www.nea.com.
AMMONUL and BUPHENYL are registered trademarks of Ucyclyd Pharma, Inc.
Full prescribing information for AMMONULŪ and BUPHENYLŪ are available at www.Ammonul.com and www.Buphenyl.com, respectively, or by contacting Hyperion Therapeutics, Inc.
Source: New Enterprise Associates
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.